Physician profile
Nanda Ramsaroop
NPI 1922048032
$5,313.34
in general payments reported to CMS, 2019-2025
26 companies · $60.00 in 2025
The $60.00 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $725 · 2021: $980 · 2022: $912 · 2023: $1,254 · 2024: $572 · 2025: $60.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.86 |
| Education | $278.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $791.77 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $722.51 | 2020-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals Lp | $666.65 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $521.85 | 2019-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $504.08 | 2019-2024 | Jardiance, Glyxambi, Tradjenta |
| Novo Nordisk INC | $487.14 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $235.18 | 2019-2021 | |
| Abbvie INC. | $231.61 | 2022-2024 | |
| Pfizer INC. | $208.29 | 2019-2023 | |
| Abbott Laboratories | $207.53 | 2021-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $165.91 | 2020-2024 | Mounjaro, Zepbound |
| Redhill Biopharma INC. | $104.58 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $93.16 | 2019-2023 | Xarelto |
| Daiichi Sankyo INC. | $72.34 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $70.51 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $37.50 | 2021-2022 | |
| Genentech USA, INC. | $29.03 | 2019-2020 | |
| Amarin Pharma, INC. | $23.28 | 2019 | |
| Dermira, INC. | $23.21 | 2020 | |
| Boston Scientific Corporation | $21.25 | 2020 | |
| Novartis Pharmaceuticals Corporation | $20.49 | 2023 | |
| Bausch Health US, LLC | $17.49 | 2021 | |
| Currax Pharmaceuticals LLC | $17.34 | 2023 | Nexletol, Onzetra Xsail, Nexlizet |
| Teva Pharmaceuticals USA, INC. | $16.79 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.79 | 2019 | |
| Medtronic Minimed, INC. | $11.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nanda Ramsaroop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.